Prot #CBGJ398XUS04: Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations

Project: Research project

Project Details

StatusFinished
Effective start/end date10/3/14 → 12/31/18

Funding

  • United BioSource LLC (Prot #CBGJ398XUS04 // Prot #CBGJ398XUS04)
  • Novartis Pharmaceuticals Corporation (Prot #CBGJ398XUS04 // Prot #CBGJ398XUS04)